Breaking News Instant updates and real-time market news.

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

, SVRA

Savara

$2.49

-0.14 (-5.32%)

18:46
09/18/19
09/18
18:46
09/18/19
18:46

Fly Intel: After Hours Movers

UP AFTER EARNINGS: Herman Miller (MLHR) up 9.1%. ALSO HIGHER: Savara (SVRA) up 11.1% after announcing presentation of additional data for Molgradex at ERS... China Biologic (CBPO) up 7.6% after disclosing "going private" offer from Beachhead Holdings and Citic Capital... NCR Corp (NCR) up 3.4% after backing FY19 guidance, retiring convertible preferred stock... Microsoft (MSFT) up 1.3% after announcing new $40B buyback, raising dividend by 11%... Tandem Diabetes (TNDM) up 1.3% after disclosing t:slim X2 pump results. DOWN AFTER EARNINGS: U.S. Steel (X) down 8.7% after negative Q3 pre-announcement. ALSO LOWER: Provention Bio (PRVB) down 9.4% after equity offering... Plains All American (PAA) down 1.7% after secondary offerings... Costco (COST) down 0.8% after being cut to Underperform at Bernstein. Movers as of 18:30ET.

MLHR

Herman Miller

$44.48

-0.02 (-0.04%)

SVRA

Savara

$2.49

-0.14 (-5.32%)

CBPO

China Biologic

$103.19

0.37 (0.36%)

NCR

NCR Corp.

$33.62

0.77 (2.34%)

MSFT

Microsoft

$138.53

1.13 (0.82%)

TNDM

TNDM

X

U.S. Steel

$12.45

-0.51 (-3.94%)

PRVB

Provention Bio

$9.70

0.33 (3.52%)

PAA

Plains All American

$21.87

-0.315 (-1.42%)

COST

Costco

$292.47

0.96 (0.33%)

  • 19

    Sep

  • 19

    Sep

  • 23

    Sep

  • 01

    Oct

  • 02

    Oct

  • 03

    Oct

  • 21

    Oct

  • 22

    Oct

  • 27

    Oct

  • 05

    Nov

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

MLHR Herman Miller
$44.48

-0.02 (-0.04%)

05/01/19
SIDC
05/01/19
DOWNGRADE
Target $41
SIDC
Neutral
Herman Miller downgraded to Neutral on valuation at Sidoti
As previously reported, Sidoti analyst Gregory Burns downgraded Herman Miller to Neutral from Buy, citing valuation with the stock now trading near his unchanged price target of $41. Investments in the Consumer segment are driving solid revenue growth, but margin expansion is lagging, said Burns, who acknowledges the potential for upside if the company is able to execute. However, he thinks headwinds will persist, at least in the near-term, he tells investors.
05/01/19
SIDC
05/01/19
DOWNGRADE
SIDC
Neutral
Herman Miller downgraded to Neutral from Buy at Sidoti
SVRA Savara
$2.49

-0.14 (-5.32%)

06/13/19
JMPS
06/13/19
DOWNGRADE
JMPS
Market Perform
Savara downgraded to Market Perform from Outperform at JMP Securities
JMP Securities analyst Liisa Bayko downgraded Savara to Market Perform from Outperform following the failure of the Phase 3 Impala study to meet its primary efficacy endpoint. The Phase 3 study of Molgradex in pulmonary alveolar proteinosis failed to hit the primary endpoint of A-aDO2 gradient reduction due to a higher than expected placebo effect, which is "disappointing setback for the program," Bayko tells investors in a research note. The analyst believes another study will be necessary to support approval.
06/13/19
LTCO
06/13/19
DOWNGRADE
LTCO
Neutral
Savara downgraded to Neutral from Buy at Ladenburg
06/13/19
HCWC
06/13/19
NO CHANGE
Target $6
HCWC
Buy
Savara price target lowered to $6 from $22 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein lowered his price target for Savara to $6 from $22 saying the company reported "highly disappointing" topline results from its pivotal Phase 3 Impala trial. He keeps a Buy rating on the shares.
06/13/19
ADAM
06/13/19
NO CHANGE
Target $15
ADAM
Buy
Savara price target lowered to $15 from $22 at Canaccord
Canaccord analyst Dewey Steadman lowered his price target on Savara to $15 from $22 following its disappointing IMPALA read showing Molgradex can work in PAP despite the IMPALA trial not adequately designed to prove the drug's effectiveness in the orphan designation. The analyst said he will treat IMPALA as essentially a Phase 2 from which the company can build an affective Phase 3 program that could eventually win approval. Steadman maintained his Buy rating on Savara shares.
CBPO China Biologic
$103.19

0.37 (0.36%)

03/11/19
JEFF
03/11/19
DOWNGRADE
Target $62
JEFF
Underperform
Jefferies downgrades China Biologic to Underperform with $62 price target
Jefferies analyst Johnny Wong downgraded China Biologic Products Holdings to Underperform from Hold and lowered his price target for the shares to $62 from $67. The company's short-term prospects could have "more potential downside"as the nationwide ancillary drug list could drastically cut sales of placenta polypeptide while increasing selling expenses, Wong tells investors in a research note. The analyst sees a "strong possibility" that placenta polypeptide could be included in the nationwide ancillary drug list later this year, which he notes would further affect China Biologic's sales.
03/11/19
JEFF
03/11/19
DOWNGRADE
Target $62
JEFF
Underperform
China Biologic downgraded to Underperform from Hold at Jefferies
Jefferies analyst Johnny Wong downgraded China Biologic Products Holdings to Underperform and lowered his price target for the shares to $62 from $67.
11/05/18
MSCO
11/05/18
DOWNGRADE
MSCO
Equal Weight
China Biologic downgraded to Equal Weight from Overweight at Morgan Stanley
NCR NCR Corp.
$33.62

0.77 (2.34%)

09/18/19
09/18/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Papa John's (PZZA) initiated with a Perform at Oppenheimer. 2. Adesto Technologies (IOTS) initiated with a Buy at Loop Capital. 3. American Eagle (AEO) initiated with a Buy at DA Davidson while Abercrombie & Fitch (ANF) was initiated with a Neutral. 4. Canopy Growth (CGC) initiated with a Perform at Oppenheimer. 5. NCR Corp. (NCR) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/25/19
JPMS
03/25/19
DOWNGRADE
Target $32
JPMS
Neutral
NCR Corp. downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Paul Coster downgraded NCR Corp. to Neutral from Overweight with an unchanged price target of $32. The stock looks attractively valued but its mix-shift toward software and software-as-a-service will not be fast enough to "trigger a re-rating of the stock in the next 6-12 months," Coster tells investors in a research note. The analyst thinks NCR shares will likely be range-bound pending evidence that its new management can drive faster growth in software and SaaS.
09/18/19
WELS
09/18/19
INITIATION
Target $45
WELS
Outperform
NCR Corp. initiated with an Outperform at Wells Fargo
Wells Fargo analyst Timothy Willi started coverage of NCR Corp. with an Outperform rating and a $45 price target. The analyst believes discounted valuation reflects the inconsistent performance in recent years as opposed to turnaround efforts under new management. He views risk/reward as favorable at current levels and believes management has taken right steps to turnaround the business.
01/08/19
DADA
01/08/19
UPGRADE
Target $30
DADA
Buy
NCR Corp upgraded to Buy from Neutral at DA Davidson
DA Davidson analyst Matt Summerville upgraded NCR Corp to Buy from Neutral and raised his price target to $30 from $27.50. The analyst points to rising consistency of the company's execution under the new leadership since the departure of CEO Bill Nuti and CFO Bob Fishman, anticipating NCR to return to positive organic growth in 2019.
MSFT Microsoft
$138.53

1.13 (0.82%)

08/22/19
08/22/19
INITIATION
Target $40

Buy
Slack Technologies initiated with a Buy at MKM Partners
As previously reported, MKM Partners analyst Rohit Kulkarni initiated Slack (WORK) with a Buy rating and a price target of $40. The analyst is positive on the company's evolution into a "central repository of information" around corporate workflows such as sales, customer service, recruiting, and accounting, saying its value proposition is "even more compelling" as a tool to "connect employees, applications, and data." While he sees Microsoft (MSFT) as a primary competitive threat to Slack in the coming years, he sees the probability of a "winner take most" scenario in enterprise collaboration software market as low.
08/29/19
WEDB
08/29/19
NO CHANGE
Target $160
WEDB
Outperform
Microsoft cloud momentum should continue, says Wedbush
Wedbush analyst Daniel Ives believes Microsoft (MSFT) remains in an enviable position heading into the rest of 2019 and 2020 on the heels of its cloud success and is firing on all cylinders around its Office 365 and Azure strategic vision based on his recent checks. So far in the September quarter, the analyst is seeing a clear acceleration of larger and more strategic enterprise cloud deals as he believes "Redmond is poised to win the lion's share of the next phase of cloud deployments vs. Amazon [AMZN] and Bezos." The shift to cloud is a major secular trend that is "significantly benefiting" Microsoft in the field and should continue its momentum heading into the next 12-18 months, he contends. Ives reiterates an Outperform rating and a $160 price target on Microsoft's shares.
09/12/19
MZHO
09/12/19
INITIATION
Target $26
MZHO
Neutral
Slack Technologies initiated with a Neutral at Mizuho
Mizuho analyst Gregg Moskowitz initiated Slack Technologies (WORK) with a Neutral rating and $26 price target. While he views the company's communications and collaboration platform as "best-in-class," Moskowitz said the competitive pressures it faces are "difficult to ignore." He thinks Microsoft's (MSFT) competing Teams service significantly reduces Slack's pricing power, the analyst said in his initiation note.
08/26/19
KEYB
08/26/19
NO CHANGE
Target $130
KEYB
Overweight
Xilinx price target lowered to $130 from $140 at KeyBanc
KeyBanc analyst John Vinh lowered his price target for Xilinx (XLNX) to $130 from $140 as he believes the launch of Microsoft's (MSFT) FPGA-as-a-Service has been postponed from Q4 to early next year due to the availability of a key software-related feature. The analyst expects Microsoft's FaaS to preview by the end of this year and go live early next year. While Vinh still believes Microsoft represents a significant opportunity longer term, he sees risk to 2020 estimates and to DCG expectations for 60% growth. Nonetheless, he reiterates an Overweight rating on Xilinx shares given long-term secular growth opportunities in 5G and Data Center.
TNDM TNDM

08/02/19
OPCO
08/02/19
NO CHANGE
Target $84
OPCO
Outperform
Tandem Diabetes price target raised to $84 from $80 at Oppenheimer
Oppenheimer analyst Steven Lichtman raised his price target for Tandem Diabetes to $84 from $80 following the company's Q2 results, saying sales exceeded expectations significantly, with sales and adjusted EBITDA guidance both raised. In a research note to investors, Lichtman says looking forward, the key drivers in his focus are the launch of Control-IQ in Q4 a now building renewal cycle, international expansion and what he continues to believe is an under-appreciated t:sport opportunity.
08/01/19
PIPR
08/01/19
NO CHANGE
PIPR
Overweight
Piper says nonprofit's survey positive for Tandem, DexCom, Insulet
Piper Jaffray analyst JP McKim noted that T1D Exchange, a nonprofit research organization, released its findings of a survey of Type 1 Diabetes patients. The survey results lead him to believe "there is plenty of growth just in the Type 1 market ahead" for Dexcom (DXCM), to be followed by the G7 launch, which will "help unlock the Type 2 market." The survey also points to "an unprecedented level of market share taking" by Tandem (TNDM) in the first 6 months of the year and was positive for Insulet (PODD) as well, McKim tells investors. He has Overweight ratings on all three stocks mentioned.
07/11/19
CHLM
07/11/19
NO CHANGE
Target $84
CHLM
Buy
Tandem Diabetes a clear beneficiary of Medtronic recall, says Craig-Hallum
Craig-Hallum analyst Alexander Nowak believes Tandem Diabetes (TNDM) and to a lesser extent Insulet (PODD) are the "clear beneficiaries" of the FDA recalling 189,000 Medtronic (MDT) 600-series pumps. The recall should further assist Tandem's share gains over the next several quarters and perhaps years, Nowak tells investors in a research note. And while UnitedHealth (UNH) has an exclusive contract with Medtronic Diabetes, the recall is further data Tandem can use to negotiate with UnitedHealth and argue for inclusion in its network, adds the analyst. He reiterates a Buy rating on shares of Tandem Diabetes with an $84 price target.
06/17/19
LSCM
06/17/19
NO CHANGE
Target $100
LSCM
Buy
Lake Street reiterates Buy on Tandem Diabetes with $100 price target
Lake Street analyst Brooks O'Neil says shares of Tandem Diabetes fell sharply last week following the release of positive results from two "critical" studies of the t:slim X2 Insulin Pump with Control-IQ Technology. "This reminds us of the reaction of the stock following the release of exceptional Q1 results delivered by Tandem on April 30, 2019," O'Neil tells investors in a research note. While both industry leaders and upstarts are touting "next generation" platforms, only Tandem has conducted a pivotal trial to prove its next gen system's capabilities, O'Neil adds. He reiterates a Buy rating on the shares with a $100 price target.
X U.S. Steel
$12.45

-0.51 (-3.94%)

06/19/19
06/19/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lamb Weston (LW) upgraded to Buy from Neutral at Goldman Sachs with analyst Adam Samuelson saying the shares offer an "attractive valuation risk/reward," after declining 18.6% year-to-date. 2. TripAdvisor (TRIP) upgraded to Buy from Hold at SunTrust with analyst Naved Khan noting that the market valuation is placing more emphasis on the company's EBITDA multiple of the slower-growing Core business, even though its Experiences segment has generated annual growth of over 30% and now represents nearly a third of total sales. 3. Six Flags (SIX) upgraded to Outperform from Neutral at Wedbush with analyst James Hardiman stating believes that a number of potential catalysts line up nicely for the company, most notably Per-Capita spending improvements driven by the Membership 2.0 program, positive news flow from the company's international business and easy weather comparisons. 4. National CineMedia (NCMI) upgraded to Outperform from Neutral at Wedbush with analyst Michael Pachter saying he is less concerned about reserved seating driving later arrivals as the company has shown that it can recoup ad dollars elsewhere. 5. U.S. Steel (X) upgraded to Buy from Sell at Vertical Group with analyst Gordon Johnson after the company did the "unthinkable" and idled two U.S. plants and one in the EU. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/19
DBAB
06/27/19
NO CHANGE
DBAB
Hold
Deutsche Bank places 'Catalyst Call' buy on Steel Dynamics
Deutsche Bank analyst Chris Terry placed a "Catalyst Call" buy on shares of Steel Dynamics (STLD) with the stock down 17% since late November 2018. The analyst keeps a Hold rating on the name but sees a shorter term opportunity for upside. Steel Dynamics is ~70% exposed to flat steel, where pricing is now likely bottoming, Terry tells investors in a research note. In addition, U.S. Steel (X) recently announced 2.5mt of capacity curtailments which could improve sentiment towards pricing and the future supply/demand balance, adds the analyst.
06/26/19
JEFF
06/26/19
NO CHANGE
JEFF
Nucor flat rolled price increase likely to help sentiment, says Jefferies
After Nucor (NUE) announced a $40/t flat rolled price increase yesterday, which was the first increase since February, Jefferies analyst Martin Englert said he thinks peers are likely to follow. While the increase may not immediately raise prices, it is a move in the right direction that aids more positive sector sentiment, Englert tell investors. The analyst, who advises investors to increase exposure to steel stocks, names Nucor, Steel Dynamics (STLD), Cleveland-Cliffs (CLF) and Commercial Metals (CMC) as his top U.S. picks Other publicly traded companies in the steel space include AK Steel (AKS), ArcelorMittal (MT), TimkenSteel (TMST) and U.S. Steel (X).
06/19/19
VERF
06/19/19
UPGRADE
VERF
Buy
U.S. Steel upgraded to Buy from Sell at Vertical Group
Vertical Group analyst Gordon Johnson double upgraded U.S. Steel to Buy from Sell after the company did the "unthinkable" and idled two U.S. plants and one in the EU. He sees the stock likely moving higher after the actions, he tells investors.
PRVB Provention Bio
$9.70

0.33 (3.52%)

08/05/19
LEER
08/05/19
NO CHANGE
Target $35
LEER
Outperform
Provention Bio price target raised to $35 from $17 at SVB Leerink
SVB Leerink analyst Pasha Sarraf raised his price target for Provention Bio to $35 from $17 after the FDA granted breakthrough designation for teplizumab. The analyst believes the company will now pursue an expedited approval for teplizumab using the At-Risk trial and other historical datasets for registrational purposes, with a type I prevention indication. Sarraf reiterates an Outperform rating on the shares.
06/10/19
CHDN
06/10/19
INITIATION
Target $20
CHDN
Buy
Provention Bio initiated with a Buy at Chardan
Chardan initiated Provention Bio with a Buy and $20 price target.
02/22/19
LEER
02/22/19
INITIATION
Target $6
LEER
Outperform
Provention Bio initiated with an Outperform at SVB Leerink
SVP Leerink analyst Pasha Sarraf initiated Provention Bio with an Outperform rating and $6 price target. The company's small team of experienced drug developers is aggregating assets through leveraged strategic partnerships, Sarraf tells investors in a research note.
01/18/19
HCWC
01/18/19
INITIATION
Target $7.5
HCWC
Buy
Provention Bio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Provention Bio with a Buy rating and $7.50 price target. Provention is a "virtual, rapidly emerging biotechnology company focused on treatment of inflammatory and autoimmune diseases," Selvaraju tells investors in a research note. He sees "substantial" market opportunities for the company that underserved by existing drugs.
PAA Plains All American
$21.87

-0.315 (-1.42%)

07/17/19
PIPR
07/17/19
INITIATION
Target $31
PIPR
Overweight
Plains All American initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Pearce Hammond started Plains All American with an Overweight rating and $31 price target. The analyst likes the company's "industry leading" Permian leverage and improving balance sheet.
06/14/19
RBCM
06/14/19
NO CHANGE
Target $27
RBCM
Sector Perform
Plains All American price target lowered to $27 from $29 at RBC Capital
RBC Capital analyst Elvira Scotto lowered her price target on Plains All American to $27 and kept her Sector Perform rating. The analyst notes that while the company offers a "greatly improved balance sheet" and stands to benefit from the Permian Basin crude oil production growth, it also faces rising "competitive headwinds" in the near term.
06/13/19
WOLF
06/13/19
UPGRADE
Target $27
WOLF
Outperform
Plains All American upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research analyst Keith Stanley upgraded Plains All American to Outperform from Peer Perform, stating that the balance sheet "is fixed," management is focused on capital discipline and the announcement of Red Oak further improves its growth outlook. He raised his price target on the shares to $27 from $26.
09/03/19
SCOT
09/03/19
INITIATION
Target $28
SCOT
Outperform
Plains All American initiated with an Outperform at Scotiabank
Scotiabank started Plains All American Pipeline with an Outperform rating and $28 price target.
COST Costco
$292.47

0.96 (0.33%)

09/18/19
SBSH
09/18/19
NO CHANGE
Target $135
SBSH
Buy
Walmart price target raised to $135 from $129 at Citi
Citi analyst Gregory Badishkanian raised his price target for Walmart (WMT) to $135 from $129 after taking over coverage of the name. The analyst keeps a Buy rating on the shares. An aggressive omni-channel strategy, low-prices, grocery offerings, and productivity initiatives should drive long-term sales growth and margin upside, Badishkanian tells investors in a research note. The analyst also took over coverage of BJ's Wholesale (BJ) with an unchanged Buy rating and $32 price target, as well as Costco Wholesale (COST) with an unchanged Neutral rating and price target of $303, up from $281.
09/18/19
BERN
09/18/19
DOWNGRADE
BERN
Underperform
Costco downgraded to Underperform from Market Perform at Bernstein
09/11/19
09/11/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Dave & Buster's (PLAY) downgraded to Market Perform from Outperform at William Blair and Raymond James, and to Hold from Buy at Loop Capital. 2. Fortis (FTS) downgraded to Market Perform from Outperform at BMO Capital with analyst Ben Pham saying he believes the current valuation already reflects the company's positive fundamentals. 3. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Hold from Buy at HSBC. 4. HD Supply (HDS) downgraded to Neutral from Buy at Buckingham and to Neutral from Outperform at Baird. 5. Costco (COST) downgraded to Perform from Outperform at Oppenheimer with analyst Rupesh Parikh citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/19
BERN
09/18/19
DOWNGRADE
Target $230
BERN
Underperform
Bernstein downgrades Costco to Underperform on 'membership exhaustion' risk
Bernstein analyst Brandon Fletcher downgraded after the close Costco Wholesale to Underperform from Market Perform with a price target of $230, up from $220. The shares closed Wednesday up $1.02 to $292.43. "Membership exhaustion" poses risks to the company's U.S. and international growth, Fletcher tells investors in a research note. The analyst believes Costco members could reevaluate their spending and membership fees competitors get more aggressive. Further, he sees the company's growth in China coming in slower than most investors think.

TODAY'S FREE FLY STORIES

03:15
10/21/19
10/21
03:15
10/21/19
03:15
General news
FX Action: USD-CAD posted a fresh two-and-a-half-month low »

FX Action: USD-CAD posted…

03:00
10/21/19
10/21
03:00
10/21/19
03:00
General news
Asian Market Update: »

Asian Market Update: It…

EDPFY

Energias de Portugal

$0.00

(0.00%)

19:56
10/20/19
10/20
19:56
10/20/19
19:56
Upgrade
Energias de Portugal rating change at JPMorgan »

Energias de Portugal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ARWR

Arrowhead

$35.98

-0.63 (-1.72%)

19:54
10/20/19
10/20
19:54
10/20/19
19:54
Recommendations
Arrowhead analyst commentary at Piper Jaffray »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

19:31
10/20/19
10/20
19:31
10/20/19
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BA

Boeing

$344.09

-25.04 (-6.78%)

FB

Facebook

$185.96

-4.435 (-2.33%)

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$130.91

-1.46 (-1.10%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

GMVHF

GVC Holdings

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

CPTA

Capitala Finance

$9.11

0.13 (1.45%)

19:23
10/20/19
10/20
19:23
10/20/19
19:23
Downgrade
Capitala Finance rating change at Keefe Bruyette »

Capitala downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

GM

General Motors

$36.19

-0.01 (-0.03%)

, F

Ford

$9.29

0.18 (1.98%)

19:13
10/20/19
10/20
19:13
10/20/19
19:13
Periodicals
GM contract terms may be hard for rivals, NY Times says »

General Motors (GM) made…

GM

General Motors

$36.19

-0.01 (-0.03%)

F

Ford

$9.29

0.18 (1.98%)

FCAU

Fiat Chrysler

$13.22

0.085 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

TRI

Thomson Reuters

$66.73

-0.08 (-0.12%)

19:09
10/20/19
10/20
19:09
10/20/19
19:09
Hot Stocks
Thomson Reuters issues statement on CEO succession planning »

Thomson Reuters has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

T

AT&T

$38.46

0.64 (1.69%)

, CMCSA

Comcast

$45.58

-0.36 (-0.78%)

16:45
10/20/19
10/20
16:45
10/20/19
16:45
On The Fly
Box Office Battle: 'Maleficent 2' wins weekend with just $36M »

"Box Office Battle" is…

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.23

-0.83 (-1.38%)

LGF.A

Lionsgate

$8.47

-0.13 (-1.51%)

LGF.B

Lionsgate

$7.96

-0.11 (-1.36%)

DIS

Disney

$130.91

-1.46 (-1.10%)

VIAB

Viacom

$22.05

-0.56 (-2.48%)

VIA

Viacom

$24.80

-0.8 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

FB

Facebook

$185.96

-4.435 (-2.33%)

16:16
10/20/19
10/20
16:16
10/20/19
16:16
Periodicals
Facebook open to currency-pegged stablecoins, Reuters reports »

Facebook, facing growing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

WYNN

Wynn Resorts

$113.55

-0.49 (-0.43%)

16:12
10/20/19
10/20
16:12
10/20/19
16:12
Periodicals
Ex-Wynn Resorts worker claims company spied on him, WSJ reports »

A former Wynn Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

16:01
10/20/19
10/20
16:01
10/20/19
16:01
Periodicals
SoftBank seeking to avoid WeWork's liabilities with new investment, Reuters says »

SoftBank (SFTBY) is…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 21

    Nov

  • 14

    Jan

GM

General Motors

$36.19

-0.01 (-0.03%)

15:53
10/20/19
10/20
15:53
10/20/19
15:53
Periodicals
GM strike continues, pain felt by Midwest workers deepens, WSJ says »

With the strike at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

15:43
10/20/19
10/20
15:43
10/20/19
15:43
Periodicals
Boeing expresses regret over ex-pilot's 737 Max messages, Reuters says »

Boeing said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ED

Consolidated Edison

$91.54

0.22 (0.24%)

, MA

MasterCard

$270.90

-5.74 (-2.07%)

15:38
10/20/19
10/20
15:38
10/20/19
15:38
Hot Stocks
MasterCard expands Bill Pay Exchange partners »

Mastercard (MA) has…

ED

Consolidated Edison

$91.54

0.22 (0.24%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

LAZ

Lazard

$37.09

0.06 (0.16%)

15:33
10/20/19
10/20
15:33
10/20/19
15:33
Hot Stocks
Lazard announces resignation of Deputy CEO of Financial Advisory »

Lazard announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

  • 07

    Nov

ALXN

Alexion

$98.41

-1.53 (-1.53%)

15:25
10/20/19
10/20
15:25
10/20/19
15:25
Hot Stocks
Alexion ULTOMIRIS receives FDA approval for Atypical Hemolytic Uremic Syndrome »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

, POST

Post Holdings

$100.65

-0.8 (-0.79%)

09:49
10/20/19
10/20
09:49
10/20/19
09:49
On The Fly
Opening Day: BellRing climbs after $480M IPO »

BellRing Brands (BRBR)…

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

POST

Post Holdings

$100.65

-0.8 (-0.79%)

IPHA

Innate Pharma

$6.05

0.19 (3.24%)

KRAT

Karat Packaging

$0.00

(0.00%)

ONEW

OneWater Marine

$0.00

(0.00%)

BRP

BRP Group

$0.00

(0.00%)

PGNY

Progyny

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 07

    Dec

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.